SELLAS LIFE SCIENCES GROUP I (SLS) Stock Fundamental Analysis
NASDAQ:SLS - Nasdaq - US81642T2096 - Common Stock
Taking everything into account, SLS scores 2 out of 10 in our fundamental rating. SLS was compared to 574 industry peers in the Biotechnology industry. The financial health of SLS is average, but there are quite some concerns on its profitability. SLS is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year SLS has reported negative net income.
SLS had a negative operating cash flow in the past year.
SLS had negative earnings in each of the past 5 years.
In the past 5 years SLS always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of SLS (-227.81%) is worse than 91.68% of its industry peers.
SLS has a worse Return On Equity (-1182.35%) than 83.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -227.81% | ||
| ROE | -1182.35% | ||
| ROIC | N/A |
ROA(3y)-292.14%
ROA(5y)-216.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SLS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SLS has more shares outstanding
SLS has more shares outstanding than it did 5 years ago.
SLS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -25.87, we must say that SLS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -25.87, SLS is not doing good in the industry: 89.38% of the companies in the same industry are doing better.
There is no outstanding debt for SLS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -25.87 |
ROIC/WACCN/A
WACC10.71%
2.3 Liquidity
A Current Ratio of 1.02 indicates that SLS should not have too much problems paying its short term obligations.
With a Current ratio value of 1.02, SLS is not doing good in the industry: 88.67% of the companies in the same industry are doing better.
SLS has a Quick Ratio of 1.02. This is a normal value and indicates that SLS is financially healthy and should not expect problems in meeting its short term obligations.
SLS has a worse Quick ratio (1.02) than 87.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.02 | ||
| Quick Ratio | 1.02 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 55.19% over the past year.
SLS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)55.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.7%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
SLS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.08% yearly.
SLS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 64.94% yearly.
EPS Next Y60.17%
EPS Next 2Y28.48%
EPS Next 3Y17.89%
EPS Next 5Y23.08%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y8.11%
Revenue Next 5Y64.94%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SLS. In the last year negative earnings were reported.
Also next year SLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as SLS's earnings are expected to grow with 17.89% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.48%
EPS Next 3Y17.89%
5. Dividend
5.1 Amount
No dividends for SLS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SELLAS LIFE SCIENCES GROUP I
NASDAQ:SLS (1/17/2025, 8:27:34 PM)
After market: 1.1001 +0.04 (+3.78%)1.06
+0.08 (+7.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners9.54%
Inst Owner Change0%
Ins Owners0.16%
Ins Owner Change-5.56%
Market Cap74.60M
Analysts82.86
Price Target5.95 (461.32%)
Short Float %11.35%
Short Ratio6.14
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.98%
Min EPS beat(2)-29.95%
Max EPS beat(2)21.99%
EPS beat(4)1
Avg EPS beat(4)-2524.49%
Min EPS beat(4)-8900.9%
Max EPS beat(4)21.99%
EPS beat(8)3
Avg EPS beat(8)-1270.51%
EPS beat(12)3
Avg EPS beat(12)-864.45%
EPS beat(16)5
Avg EPS beat(16)-648.82%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-0.34%
EPS NY rev (3m)6.73%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 25.61 | ||
| P/tB | 74.68 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.69
EYN/A
EPS(NY)-0.48
Fwd EYN/A
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.46
OCFYN/A
SpS0
BVpS0.04
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -227.81% | ||
| ROE | -1182.35% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-292.14%
ROA(5y)-216.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.02 | ||
| Quick Ratio | 1.02 | ||
| Altman-Z | -25.87 |
F-Score3
WACC10.71%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.7%
EPS Next Y60.17%
EPS Next 2Y28.48%
EPS Next 3Y17.89%
EPS Next 5Y23.08%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y8.11%
Revenue Next 5Y64.94%
EBIT growth 1Y5.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-24.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-35.37%
OCF growth 3YN/A
OCF growth 5YN/A